Page last updated: 2024-09-05

lapatinib and Osteonecrosis

lapatinib has been researched along with Osteonecrosis in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Heinemann, V; Rack, B; Salat, C; Schindlbeck, C; Sommer, H; Walther, J	1

Reviews

1 review(s) available for lapatinib and Osteonecrosis

Article	Year
[Metastatic breast cancer--new methods of treatment]. MMW Fortschritte der Medizin, 2008, Jan-17, Volume: 150, Issue:1-2 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Clinical Trials, Phase III as Topic; Diphosphonates; Female; Histocytochemistry; Humans; Lapatinib; Neoplasm Metastasis; Osteonecrosis; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Risk Factors; Signal Transduction; Time Factors; Trastuzumab	2008

Article

Year

[Metastatic breast cancer--new methods of treatment].

MMW Fortschritte der Medizin, 2008, Jan-17, Volume: 150, Issue:1-2

Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Clinical Trials, Phase III as Topic; Diphosphonates; Female; Histocytochemistry; Humans; Lapatinib; Neoplasm Metastasis; Osteonecrosis; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Risk Factors; Signal Transduction; Time Factors; Trastuzumab

2008